Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 02, 2026
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Journal: The New England journal of medicine
Published: July 29, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and Outcomes.
Journal: AIDS patient care and STDs
Published: June 05, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: March 17, 2026
Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021-2024.
Journal: Infectious diseases and therapy
Published: February 05, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: January 22, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
Journal: Lancet (London, England)
Published: August 04, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.
Journal: Open forum infectious diseases
Published: June 25, 2025
Last Updated: 09/26/2026